**Representative datasheet**

Sheep anti-human Factor VIII
Whole IgG from Antiserum
10 mg

<table>
<thead>
<tr>
<th>Product #</th>
<th>SAF8C-IG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot #</td>
<td>XXXX</td>
</tr>
<tr>
<td>Expiry date</td>
<td>XXXX</td>
</tr>
</tbody>
</table>

Store at –10 to -20°C

For Research Use Only. Not for use in diagnostic procedures.

**Description of Factor VIII (FVIII)**

Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of FVIII ranging in size from 200-280 kDa. The FVIII is stabilized by association with von Willebrand Factor to form a FVIII-vWF complex required for the normal survival of FVIII in vivo ($t_{1/2}$ of 8-12 hours).

FVIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process FVIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, FVIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay.

Hemophilia A is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of FVIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a FVIII protein that is partially or totally inactive. The production of neutralizing antibodies to FVIII also occurs in 5-20% of Hemophiliacs 1-3.

**References and Reviews**


**Product Specifications**

**Description:**
Vial containing XXXX ml of whole IgG representing approximately 1 ml of antiserum. Total protein is 10 mg.

**Format:**
Whole IgG, clear liquid.

**Host Animal:**
Sheep

**Immunogen:**
Human FVIII (FVIII:C) purified from concentrate.

**Concentration:**
IgG concentration is XXXX mg/ml, determined by absorbance using an extinction coefficient ($E_{1%280}$) of 13.4.

**Buffer:**
10 mM HEPES, pH 7.4, 150 mM NaCl, 50% (v/v) glycerol.

**Storage:**
Store between –10 and –20°C. Product will become viscous but will not freeze. Avoid storage in frost-free freezers. Keep vial tightly capped. Allow product to warm to room temperature and gently mix before use.

**Specificity:**
This antibody is specific for FVIII as demonstrated by immunoelectrophoresis and ELISA. When titrated on vWF-coated plates, SAF8C-IG does not demonstrate any reactivity above the non-immune sheep negative control.

**Applications:**
Suitable as a source of antibodies to Factor VIII.

**Neutralizing activity:**
XXXX Bethesda Units/ml IgG against normal plasma (Kasper CK et al, Thromb Diath Haemorrh 34:869, 1975). One Bethesda unit/ml is defined as the amount of inhibitor that resulted in 50% residual FVIII activity after 2 hours at 37°C.

**Species Cross Reactivity:**
Not determined.
Related Products:
Cat #: SAFBC-AP Sheep anti-human Factor VIII, affinity purified IgG
Cat #: SAFBC-HRP Sheep anti-human Factor VIII, whole IgG-peroxidase
Cat #: F8C-EIA Paired antibodies for Factor VIII ELISA, 4 x 96 wells
Cat #: FVIII-DP Human plasma deficient in Factor VIII, immune depleted

Visit our site (www.affinitybiologicals.com) for details.

Limited Warranty: This product is warranted to perform in accordance with its labeling and literature. Affinity Biologicals Inc. disclaims any implied warranty of merchantability or fitness for any other purposes, and in no event will Affinity Biologicals Inc. be liable for any consequential damages arising out of aforesaid express warranty.

Manufactured in Canada by:
AFFINITY BIOLOGICALS INC.
1348 Sandhill Drive
Ancaster ON CANADA L9G 4V5
Tel: (905) 304-9896
(800) 903-6020
Fax: (905) 304-9897
info@affinitybiologicals.com